Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

J von Pawel, R Jotte, DR Spigel… - Journal of clinical …, 2014 - ascopubs.org
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …
被引用次数：355 相关文章

[引用][C] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

R Jotte, DR Spigel - Journal of Clinical Oncology, 2014 - elibrary.ru

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer [JCO article]

J von Pawel, R Jotte, DR Spigel… - Journal of clinical …, 2014 - research.manchester.ac.uk
PURPOSE: Amrubicin, a third-generation anthracycline and potent topoisomerase II
inhibitor, showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This …

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer

J von Pawel, R Jotte, DR Spigel… - Journal of clinical …, 2014 - pubmed.ncbi.nlm.nih.gov
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …
[PDF] academia.edu

[PDF][PDF] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

J von Pawel, R Jotte, DR Spigel, MER O'Brien… - J Clin Oncol, 2014 - academia.edu
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

J von Pawel, R Jotte, DR Spigel… - Journal of Clinical …, 2014 - europepmc.org
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

J von Pawel, R Jotte, DR Spigel, MER O'Brien… - Journal of Clinical …, 2014 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Amrubicin, a third-generation
anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell …

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer.

J Von Pawel, R Jotte, D Spigel, M O'Brien, M Socinski… - 2014 - christie.openrepository.com
Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed
promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III trial …
[PDF] academia.edu

[PDF][PDF] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

J von Pawel, R Jotte, DR Spigel, MER O'Brien… - J Clin Oncol, 2014 - academia.edu
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …